Simtra BioPharma Solutions, based in Parsippany, has progressed in its dual-continent expansion goals in an effort to reach a growing demand.
At its Bloomington, Indiana, facility, Simtra has added a flexible clinical line for prefilled syringes and liquid and lyophilized vials and is building a new production facility that will house three isolator commercial-scale sterile filling lines.
The company also acquired a 65-acre property nearby with more than 300,000 square feet of available space for future development. Plans for this campus include the installation of at least six additional isolator filling lines. The first new line will be a high-speed isolator vial filling line equipped with three lyophilizers dedicated to highly potent molecules and is scheduled to be operational in 2027.
Meanwhile, in Halle, Germany, the company added a state-of-the-art conjugation and purification suite and inaugurated a new building with two new high-speed isolator lines. These lines are made for one for syringes and one for liquid and lyophilized vials.
Simtra CEO Franco Negron explains their objectives.
“Our purpose is clear: to bring vital injectable products to customers and their patients worldwide,” he said. “By expanding capacity and service offerings in both the United States and Europe, we are building the infrastructure needed to support innovation and reliability, now and for the future.”
Simtra’s growth strategy is closely aligned with high-demand therapeutic areas such as oncology medicines. The company produces nearly 200 million sterile units annually and stands out with production in both North America and Europe.
